CFO transition
Mannatech, Incorporated CFO transition: Yasir Haider to succeed James Clavijo
Mannatech, Incorporated reported in a Form 8-K filed June 8, 2026 that Yasir Haider will succeed James Clavijo as Chief Financial Officer, effective June 3, 2026.
In the filing's words
the Board of Directors appointed Yasir Haider as Chief Financial Officer ("CFO") and principal financial officer of Mannatech Incorporated (the "Company") effective June 3, 2026. James Clavijo, who served as the Company's CFO since July 2024, will relinquish the role to Mr. Haider.
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | Mannatech, Incorporated (MTEX) |
|---|---|
| Event | Transition |
| Incoming | Yasir Haider |
| Outgoing | James Clavijo |
| Title in the filing | Chief Financial Officer |
| Effective | June 3, 2026 |
| 8-K filed | June 8, 2026 |
| Internal promotion | Yes |
| Prior role (per filing) | Controller, Mannatech, Incorporated |
| SEC CIK | 0001056358 |
Mannatech, Incorporated reported this change in a Form 8-K, Item 5.02, filed June 8, 2026. The filing's own words are quoted above.
Other records naming Yasir Haider
1The incoming officer on this record, matched by name. Career line.
2026-04-15 · 10-K signature
Yasir Haider signed Mannatech, Incorporated's annual report as Interim Chief Financial Officer (principal financial officer)
Also filed in June 2026
Other CFO moves on the record that month. All moves.
4 months ago· 2026-06-30TransitionBANX
ArrowMark Financial Corp. CFO transition: Katherine Jones to succeed Patrick Farrell
4 months ago· 2026-06-30InterimIMNN
Imunon, Inc. names Josh Blacher interim CFO
4 months ago· 2026-06-30TransitionRANI
Rani Therapeutics Holdings, Inc. CFO transition: Nicholas M. Maestas to succeed Svai Sanford
4 months ago· 2026-06-29InterimCVKD
Cadrenal Therapeutics, Inc. names John P. Sharp interim CFO
4 months ago· 2026-06-29TransitionGCO
Genesco Inc. CFO transition: Jonathan Collins to succeed Mimi E. Vaughn
4 months ago· 2026-06-29TransitionTNYA
Tenaya Therapeutics, Inc. CFO transition: Eric Hyllengren, M.B.A. to succeed Faraz Ali, M.B.A.
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26
Something wrong about Yasir Haider? Send a correction with the primary source.